Oxbryta - direct healthcare professional communication (DHPC)

voxelotor
DHPCHuman

German is available via eTranslation, the European Commission's machine translation service.

Translate to German | Important information about machine translation

Über

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Dokumente

Direct healthcare professional communication (DHPC) : Oxbryta (voxelotor): Suspension of EU marketing authorisation

English (EN) (125.21 KB - PDF)

Erstmals veröffentlicht:
Ansicht

Key facts

Medicine name
Oxbryta
Active substance
voxelotor
Therapeutic area (MeSH)
  • Anemia
  • Anemia, Hemolytic
  • Anemia, Sickle Cell
Procedure number
EMEA/H/A-20/1538/C/004869/0014
Regulatory outcome
Suspension
DHPC type
Referral - Article 20 procedure
Human ATC codes
B06AX03
Dissemination date
Related medicines
Oxbryta

Share this page